These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9802773)

  • 1. Micronized fenofibrate in the management of dyslipidemia.
    Steiner G
    Diabetes Care; 1998 Nov; 21(11):2039-40. PubMed ID: 9802773
    [No Abstract]   [Full Text] [Related]  

  • 2. [Reversibility of severe hyperlipemia secondary to indinavir with micronized phenofibrate].
    de Luis DA; Aller R; Rachiller P; Ignacio Tortosa J
    Med Clin (Barc); 1999 Nov; 113(18):716-7. PubMed ID: 10650577
    [No Abstract]   [Full Text] [Related]  

  • 3. Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
    Sharpe M; Ormrod D; Jarvis B
    Am J Cardiovasc Drugs; 2002; 2(2):125-32; discussion 133-4. PubMed ID: 14727988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates.
    Hegele RA; Pollex RL
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1224-7. PubMed ID: 17522394
    [No Abstract]   [Full Text] [Related]  

  • 5. Monocyte suppressing action of fenofibrate.
    Okopień B; Kowalski J; Krysiak R; Łabuzek K; Stachura-Kułach A; Kułach A; Zieliński M; Herman ZS
    Pharmacol Rep; 2005; 57(3):367-72. PubMed ID: 15985720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
    Kiortsis DN; Elisaf MS
    Fundam Clin Pharmacol; 2001 Dec; 15(6):401-3. PubMed ID: 11860528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micronized fenofibrate: a new fibric acid hypolipidemic agent.
    Guay DR
    Ann Pharmacother; 1999 Oct; 33(10):1083-103. PubMed ID: 10534222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.
    Wysocki J; Belowski D; Kalina M; Kochanski L; Okopien B; Kalina Z
    Int J Clin Pharmacol Ther; 2004 Apr; 42(4):212-7. PubMed ID: 15124979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.
    Zhu S; Su G; Meng QH
    Clin Chem; 2006 Nov; 52(11):2036-42. PubMed ID: 16990410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM
    Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of fenofibrate on serum uric acid levels.
    Liamis G; Bairaktari ET; Elisaf MS
    Am J Kidney Dis; 1999 Sep; 34(3):594. PubMed ID: 10469875
    [No Abstract]   [Full Text] [Related]  

  • 12. Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor.
    de Luis DA; Bachiller P; Aller R
    Nutrition; 2001 May; 17(5):414-5. PubMed ID: 11377136
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
    Bostom AG
    Lancet; 2001 Nov; 358(9295):1811-2. PubMed ID: 11734262
    [No Abstract]   [Full Text] [Related]  

  • 14. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum].
    Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L
    Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hyperlipidemia associated with Niemann-Pick disease type B by fenofibrate.
    Choi JH; Shin YL; Kim GH; Hong SJ; Yoo HW
    Eur J Pediatr; 2006 Feb; 165(2):138-9. PubMed ID: 16211396
    [No Abstract]   [Full Text] [Related]  

  • 16. Fenofibrate and diabetic retinopathy.
    Fagan XJ; Chong EW
    Clin Exp Ophthalmol; 2015; 43(4):297-9. PubMed ID: 26099043
    [No Abstract]   [Full Text] [Related]  

  • 17. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
    Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pleiotrophic effect of anti-hyperlipemic agents].
    Morishita R
    Nihon Naika Gakkai Zasshi; 2001 Oct; 90(10):2017-22. PubMed ID: 11769493
    [No Abstract]   [Full Text] [Related]  

  • 19. Fibrates and homocysteine.
    Young IS; Woodside JV
    Nutrition; 2001; 17(11-12):973-4. PubMed ID: 11744353
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.